Background: Hyperkalemia is a clinically relevant disorder across the cardiorenal continuum. In Central America and the Dominican Republic, there are no published systematic descriptions of real-world clinical practices or the degree of alignment of these practices with the most recent hyperkalemia management guidelines. Objective: To characterize physicians perceptions and therapeutic behaviors regarding hyperkalemia, including diagnostic thresholds, criteria for intervention and referral, management strategies, and access to potassium monitoring. Methods: A cross-sectional study was conducted using an online survey administered between April and June 2025 to physicians from multiple specialties across seven countries. Absolute and relative frequencies were calculated overall and stratified by specialty and country. Results: A total of 362 responses were collected. Participants were primarily from Costa Rica (32.3%), Honduras (27.9%), and Guatemala (21.0%). 37.8% of respondents reported hyperkalemia in 10% to 30% of their patients, with the most reported diagnostic threshold being serum potassium 5.5 mEq/L. Outpatient intervention was most frequently initiated at 5.5 mEq/L (55.2%), while referral to the emergency department was reported at a potassium level of 6.0 mEq/L (35.6%). Regarding management strategies, 67.0% favored an electrocardiogram prior to deciding on intervention; 93.0% reported reduction or discontinuation of drug causing hiperkalemia; and 74.0% prescribed therapies increasing potassium excretion. Access to potassium monitoring differed substantially by setting reported as 55.5% in the public versus 90.3% in the private sector. Among cardiologists, frequently used strategies for hyperkalemia in heart failure were reduction or discontinuation of mineralocorticoid receptor antagonists and increased use of loop diuretics. Nephrologists favored strict dietary modifications, loop diuretics, and the use of cation-exchange resins. Conclusions: Substantial heterogeneity was observed in hyperkalemia definitions, action thresholds, and referral criteria, along with frequent modification of renin-angiotensin-aldosterone inhibitors, and reduced access to potassium monitoring in the public sector.